ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR060

Gut Microbiome-Derived Phenyl Sulfate Contributes to Albuminuria in Diabetic Kidney Disease (Part 1)

Session Information

Category: Diabetic Kidney Disease

  • 601 Diabetic Kidney Disease: Basic

Authors

  • Kikuchi, Koichi, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan
  • Saigusa, Daisuke, Tohoku Medical Megabank Organization, Tohoku University, Sendai, Japan
  • Kanemitsu, Yoshitomi, Tohoku university Graduate school of Pharmaceutical Sciencies, Niigata, Japan
  • Matsumoto, Yotaro, Tohoku university Graduate school of Pharmaceutical Sciencies, Niigata, Japan
  • Mishima, Eikan, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan
  • Toyohara, Takafumi, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan
  • Suzuki, Takehiro, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan
  • Nagao, Shizuko, Fujita Health University, Toyoake, Aichi-ken, Japan
  • Fukuda, Shinji, Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan
  • Soga, Tomoyoshi, Institute for Advanced Biosciences, Keio University, Tsuruoka, Yamagata, Japan
  • Tomioka, Yoshihisa, Tohoku university Graduate school of Pharmaceutical Sciencies, Niigata, Japan
  • Abe, Takaaki, Tohoku University Graduate School of Medicine, Aoba-ku, Sendai, Miyagi, Japan
Background

Diabetic kidney disease (DKD) is a major cause of renal failure in urgent of breakthrough in disease management. Type 2 diabetes causes significant changes in an array of plasma metabolites, and in humans, SLCO4C1 is the only transporter contributes to transport into urine. We generated transgenic (Tg) rats overexpressing SLCO4C1 in the proximal tubule, a typical human renal excretion model. Using this model, we characterize metabolites increased in diabetic wild type, but reduced in diabetic Tg rats.

Methods

Diabetes was induced by STZ. Untargeted metabolomics was performed by UHPLC-QTOF/MS . Phenyl sulfate (PS) and other uremic toxins were measured by LC/MS/MS. Mitochondrial function was analysis by Flux analyzer. The fecal 16S rRNA were analyzed by MiSeq.

Results

PS was increase with the progression of diabetes and was decreased in Tg rats with limited proteinuria. In diabetic mouse models, PS administration induced albuminuria and podocyte damage due to mitochondrial damage. By DKD cohort analysis, the PS level is correlated with basal and 2-year progression of albuminuria. Phenol is synthesized from dietary tyrosine by gut bacterial-specific tyrosine phenol-lyase (TPL) and absorbed phenol is metabolized into PS in the liver. Administration of TPL inhibitor reduced not only circulating PS level but also albuminuria in diabetic mice. Furthermore, TPL inhibitor ameliorated renal dysfunction in adenine-induced renal failure model.
Because TPL inhibitor did not alter the major composition, the non-lethal inhibition of microbial-specific enzymes has a therapeutic advantage for the development of drug resistance.

Conclusion

PS is a modifiable cause and a target for the treatment of DKD. Chemical reduction of TPL should represent another aspect for developing drugs preventing DKD (Nat. Commun. 10: 1835, 2019).